From: Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
Study drug | Disease | Dosage | Clinical Trial | Number of patients | Results | Reference |
---|---|---|---|---|---|---|
Regorafenib | Imatinib and Sunitinib Resistant | 160 mg/day orally day 1–21 of 28 day cycle. | Phase 2 | 33 | SD 86% | [52] |
Masitinib | First line therapy | 7.5 mg/kg/day | Phase 2 | 30 | PFS 41 m | [53] |
Crenolanib | Selective for D842V mutation | - | In vitro | - | Blocks the kinase activity of PDGFRA D842V mutants. | [54] |
PTK787/ZK222584 | Imatinib resistant | 1,250 mg o.d | Phase 2 | 15 | ORR 67% | [44] |
AMG 706 | Imatinib-resistant | 600 mg daily | Phase 2 | 138 | ORR33% | [48] |